Albireo to Host KOL Event on Progressive Familial Intrahepatic Cholestasis

BOSTON, Oct. 16, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it will host a Key Opinion Leader (KOL) breakfast meeting focused on the topic of progressive familial intrahepatic cholestasis (PFIC), a pediatric orphan liver disease, at the Lotte Palace Hotel in New York City on Wednesday, October 25, 2017, from 8:00 a.m. to 9:30 a.m. ET.

The meeting will feature a presentation by Ekkehard Sturm, M.D., Ph.D., pediatric hepatologist and the head of pediatric gastroenterology-hepatology, liver and intestinal transplantation at Children’s Hospital, University of Tuebingen in Germany. Dr. Sturm will address the current therapeutic landscape and unmet medical need in the treatment of children with PFIC and will be available to answer questions following the meeting.

In addition, Albireo management will provide an overview of Albireo’s planned Phase 3 clinical program for A4250 in children with PFIC.

Dr. Sturm serves as the pediatric coordinator of the European Reference Network RARE LIVER. He has authored or co-authored more than 50 original manuscripts, reviews and case reports published in such journals as Journal of Pediatric Surgery, Pediatric Transplantation, European Journal of Pediatrics, The Lancet, Journal of Hepatology and HEPATOLOGY. In addition, he has authored six textbook chapters on topics such as PFIC, disorders of the intrahepatic bile ducts, and living donation for liver transplantation. Dr. Sturm is a member of the American Association for the Study of Liver Diseases, the German Society for Pediatric Gastroenterology and Nutrition, the German Society of Pediatrics and Adolescent Medicine, the Dutch Society for Pediatrics and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. He holds advanced degrees from Hannover Medical School in Germany and The University Medical Center Groningen in the Netherlands and trained as a post-doctoral research fellow at Yale University.

To register to attend the event, contact LifeSci Advisors, LLC at [email protected].  Advanced registration is required, as space is limited.

A live and archived webcast of the event will be available on the Investors page of Albireo’s website at http://ir.albireopharma.com.  To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. The archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo's website for at least two weeks following the event.

About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes a Phase 3 product candidate, a Phase 2 product candidate and a product candidate for which an application for regulatory approval has been submitted in Japan. Albireo was spun out from AstraZeneca in 2008.

Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

Investor Contact:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568

Media Contact:
Heather Anderson
6 Degrees
980-938-0260
[email protected]

Source: Albireo Pharma, Inc.